AIR lifts vape spend as Crown Switch PMTA waits on FDA and NGC revenue hits $2.1M

AIR Global PLC’s vaping and nicotine-pouch unit booked $2.1 million in revenue over nine months of 2026 while posting a $10.8 million adjusted EBITDA loss, and its Crown Switch pod vape remains under FDA review.

The company, which listed on Nasdaq under AIIR and earns most of its revenue from Al Fakher flavoured shisha, filed the PMTA on 5 November 2026. No marketing authorization had been announced by 13 November.

New categories bring in $2.1 million against a $10.8 million loss

Nine-month revenue in New Growth Categories fell 2.6% year on year to $2.1 million, according to the results AIR published on 12 November. The segment’s adjusted EBITDA loss narrowed to $10.8 million from $13.2 million a year earlier.

The third quarter was less flattering: NGC revenue came in at negative $0.1 million against positive $0.6 million a year earlier. AIR attributed the figure to the timing of trade incentives rather than negative physical sales volumes. The quarterly adjusted EBITDA loss narrowed to $2.9 million from $3.9 million, which AIR linked to lower operating costs and tighter spending on launches.

Group numbers moved the other way. Third-quarter revenue rose 11.1% to $99.8 million on a 5.8% increase in flavoured shisha molasses shipment volumes plus roughly 5.0% from pricing and mix. Nine-month revenue reached $306.7 million, up 6.0%, but AIR reported a $74.2 million net loss against a $38.7 million profit a year earlier, after listing and business-combination costs.

Regulatory spending reaches $3.4 million before any U.S. authorisation

AIR booked about $3.4 million in U.S. PMTA-related expenses in the first nine months of 2026, mainly consulting, advisory and research work. The company said that figure does not cover all Crown Switch development costs.

Crown Switch runs on Quantum Chip atomisation technology from Greentank Innovations, the Canadian company AIR took a $20 million equity stake in during July 2026, alongside further investment rights and long-term supply arrangements. AIR first launched the device in Germany in November 2025; German retail versions carry 2mL prefilled pods at 18mg/mL nicotine in six flavours, and the company has separately tested two 5% nicotine formulations for U.S. development.

The timeline matters for anyone tracking the U.S. entry:

AIR has not set a date for an FDA decision and said 2027 contributions from new categories depend on how the review progresses.

Shisha pays the bills while the vape bet matures

Third-quarter shisha revenue rose 25.6% to $21.9 million in the Americas, 9.4% to $64.1 million across the Middle East, Africa and Asia, and 4.9% to $13.8 million in Europe. Europe’s adjusted EBITDA of $0.9 million compared with roughly breakeven a year earlier, and AIR again pointed to excise increases and weak enforcement against illicit products.

In the shareholder letter accompanying the results, AIR said it is putting U.S. vaping ahead of nicotine pouches, citing resource constraints, prior licensing experience with vapour products and management’s expectations for profitability across nicotine categories.

That is a contrast with the U.S. pouch shelf, where the FDA’s authorised list of 67 nicotine pouch products names Helix Innovations, Modoral Brands and Swedish Match USA and states these are the only pouch products that may be lawfully sold there. AIR’s choice to lead with a pod vape puts its U.S. revenue bet on a category with no comparable entry for Crown Switch yet.

Guidance holds at 4%–6% as capex falls and leverage rises

AIR reaffirmed 2026 revenue growth guidance of 4%–6% in U.S. dollars and low- to mid-single-digit adjusted EBITDA growth.

Capital expenditure guidance dropped to $11 million–$14 million from $15 million–$18 million. The forecast year-end net debt to adjusted EBITDA ratio rose to about 2.5 times from 2.1 times, which AIR tied to bond-issuance cash flows and working-capital timing after supply-chain disruption.

At 30 September, net debt stood at $364.8 million, or 2.6 times trailing 12-month adjusted EBITDA. On 1 October, AIR completed a $425 million senior unsecured notes offering at a 7.875% coupon maturing in 2031 and used the proceeds to refinance term-loan and revolving-credit facilities.

Supply routes have already shifted: disruption around the Strait of Hormuz earlier in 2026 pushed alternative routing and changes to manufacturing and procurement. AIR expects its Romanian plant to start operating in the first quarter of 2027.

Suppliers should plan around a 2027 U.S. decision, not a 2026 launch

For manufacturers and distributors in the vaping supply chain, the numbers confirm that a PMTA submission is a cost line, not a market entry. AIR’s $3.4 million regulatory spend sits inside a segment losing $10.8 million, so component and pod suppliers tied to Crown Switch should expect U.S. volumes only after an authorisation, which the company frames as a 2027 question. VapeBrief’s analysis.

Greentank’s position is the one to watch: the chip supply arrangement gives AIR a technology partner but also concentrates its U.S. compliance case on a single atomisation platform. Distributors weighing Crown Switch listings in Europe have a 2mL, 18mg/mL product to plan around while the U.S. version stays unapproved.

AIR’s next scheduled disclosures are its full-year 2026 results; the company also plans an annual dividend of $0.28 per share starting in 2027 and up to $100 million of buybacks through December 2029, subject to cash generation and approvals. Any FDA marketing authorisation decision on Crown Switch would change the 2027 revenue picture before then.

Questions readers ask

Has the FDA authorised Crown Switch?

No. AIR submitted the PMTA on 5 November 2026 and had announced no FDA marketing authorisation as of 13 November. The company said 2027 contributions from new categories depend on the review's progress.

How much revenue does AIR's vaping business generate?

The New Growth Categories segment, which covers vaping, nicotine pouches and other inhalation products, reported $2.1 million in nine-month 2026 revenue, down 2.6%, with a $10.8 million adjusted EBITDA loss.